Orion Infusion Ltd.
DDSE:ORIONINFU236.60
BDT
-3.90
(-1.62%)
ISIN
BD0472ORINF6
Return %
Stock
S&P 500
1Y
-51.16
14.20
3Y
-26.45
81.12
5Y
172.90
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Salman Obaidul Karim
- Full Time Employees
- 563
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Oct 5, 1994
- Website
- orioninfusion.com
- Similar Companies
- Business
- Orion Infusion Ltd. is a Bangladesh-based pharmaceutical company primarily engaged in the development, manufacturing, and commercialization of large-volume parenterals (LVP) and life-saving intravenous (IV) fluids. Operating as a subsidiary of the Orion Group, the company supplies clinical formulations to hospitals, government healthcare institutions, clinics, and retail pharmaceutical distributors across Bangladesh. Orion Infusion Ltd. was incorporated in 1983 as Mala Chemical & Pharmaceuticals Industries Ltd., adopted its current name and converted to a public limited company in 1994, and is headquartered in Dhaka, Bangladesh, with primary manufacturing operations located in Maikuli, Rupganj, Narayanganj. The company specializes in a systematic range of sterile, non-pyrogenic injectable and infusion products, including intravenous rehydration and electrolyte replenishment solutions marketed under brand names such as Dextrolac, Dextropac, Dextrosal, Dianak, Hartman, Manisol, Plasmasol, Proliv, and Salpac; hypertonic and carbohydrate infusions including Electrodex-10 and Fructose-10; antimicrobial and anti-infective intravenous infusions such as Maprocin (Ciprofloxacin I.V.) and Nidazyl (Metronidazole I.V.); gastrointestinal injectables such as Ortac (Ranitidine I.V.); specialized clinical nutrition solutions, including intravenous amino acid formulations; lipid emulsions such as Intralipid; and systemic alkalizing solutions for metabolic acidosis. In recent corporate developments, Orion Infusion Ltd. initiated a major Balancing, Modernisation, Rehabilitation, and Expansion (BMRE) program at its Rupganj manufacturing plant, committing an investment of approximately Tk 20.50 crore to expand its existing IV fluid production capacity by approximately 30%, with project completion targeted for late 2026. Furthermore, the company has undertaken technical upgrades to pure-steam generation systems in compliance with current Good Manufacturing Practice (cGMP) standards and maintained active shareholder distributions, declaring a 20% cash dividend for fiscal year 2025.